Labiotech.eu Source d'actualité
Sanofi drug reduces disease activity in relapsing MS
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation...
Hier à 12:12
Swiss researchers develop new class of antibiotics to fight resistant bacteria
Health professionals are in urgent need of new antibiotics to tackle resistant bacteria. Researchers at the University of Zurich (UZH), in Switzerland, and the company Spexis, have now modified the...
Hier à 08:34
Five ophthalmology biotech companies to look out for
There are hundreds of different eye diseases, with some of the most common major eye diseases including age-related macular degeneration (AMD) – an age-related eye disease that can blur central vision...
Il y a 2 jours
Potential targets against natural killer/T-cell lymphoma found
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has discovered that a transcription factor, TOX2, was aberrantly...
Il y a 2 jours
Artificial intelligence combats lethal superbug, new antibiotic discovered
A new antibiotic called abaucin that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI). Research published in Nature Chemical Biology showed...
|SIREN / SIRET||- DE Labiotech|
Berlin Berlin DE Allemagne